MAPT and Alzheimer disease: AD is associated with reduced Aβ1-42 levels in cerebrospinal fluid (CSF) and elevated total tau (t-tau) levels in CSF determined using enzyme-linked immunosorbent and other conventional immunoassays (Formichi et al., 2006; Brier et al., 2016).